Background: Previous studies have indicated a correlation between heart failure, inflammation and poorer outcome. However, the pathogenesis and role of inflammation in acute heart failure (AHF) is incompletely studied and understood. The aim of our study was to explore the potential role of innate immunity -quantified by complement activation products (CAPs) -in pathophysiology, responses to treatment and impacts on long-term survival in AHF. Methods: In a prospective study enrolling 179 unselected patients with AHF, plasma concentrations of C4d, C3a and sC5b-9 were measured in a blinded fashion on the first day of hospitalisation and prior to discharge. The final diagnosis, including the AHF phenotype, was adjudicated by two independent cardiologists. Long-term follow-up was obtained. Findings in AHF were compared to that obtained in 75 healthy blood donors (control group). Results: Overall, concentrations of all three CAPs were significantly higher in patients with AHF than in healthy controls (all p < 0.001). In an age-adjusted subgroup analysis, significant differences could be confirmed for concentrations of C4d and sC5b-9, and these parameters further increased after 6 days of in-hospital treatment (p < 0.001). In contrast, C3a levels in AHF patients did not differ from those of the control group in the age-adjusted subgroup analysis and remained constant during hospitalisation. Concentrations of C4d, C3a and sC5b-9 were significantly higher when AHF was triggered by an infection as compared to other triggers (p < 0.001). In addition, CAP levels significantly correlated with each other (r = 0.64-0.76), but did not predict death within 2 years. Conclusions: Activation of complement with increased plasma levels of C4d and sC5b-9 at admission and increasing levels during AHF treatment seems to be associated with AHF, particularly when AHF was triggered by an infection. However, CAPs do not have a prognostic value in AHF.
Introduction
Acute heart failure (AHF) is the most common cause of hospital admission in patients older than 65 years of age and continues to have unacceptably high rates of mortality and morbidity. [1] [2] [3] [4] [5] [6] Poor outcomes in AHF may at least in part be due to our incomplete understanding of the pathophysiology of AHF. In addition, our incomplete understanding of AHF pathophysiology may have contributed to the fact that none of the currently available treatments are supported by an appropriately powered positive randomised controlled study and none of the recently completed phase III studies of novel drugs demonstrated a clear, clinically relevant benefit. 1, 2, [7] [8] [9] More in-depth knowledge of the pathogenic mechanisms being involved in AHF seems to be a prerequisite for more targeted and successful interventions. For example, in acute myocardial infarction (AMI), identification of thrombotic plaque rupture as its key pathophysiological hallmark has led to enormous treatment successes in patients suffering from AMI with antiplatelet therapy, anticoagulation, statins and early revascularisation. 10 The complement system is one of the key components of innate immunity. After activation, it has at least three physiological functions: defence against infections; bridging innate and adaptive immunity; and clearing apoptotic cells and immune complexes. The complement system achieves these functions via the opsonisation of pathogens for phagocytes, the release of inflammatory mediators and the induction of cell lysis through the formation of the membrane attack complex. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] On the other hand, inappropriate complement activation is pathogenic and may be involved in various autoimmune diseases. The complement system features more than 20 different serum proteins that are produced by a variety of cells. The interaction of these proteins constitutes a meticulously regulated cascade of activation steps ( Figure 1 ). Finally, all activation steps converge on the complement component C3. In the heart, activated C3 (C3a) causes tachycardia, impairment of atrioventricular conduction and left ventricular contractility. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Pilot studies have suggested an activation of inflammatory pathways in chronic heart failure (CHF) and regression after treatment, as well as an association between inflammation and poorer outcomes. [22] [23] [24] [25] [26] However, the pathogenic mechanisms leading to the activation of the immune system and to poorer outcomes are largely unknown. While several recent studies have examined complement components in patients with AMI, their possible roles in heart failure in general and AHF in particular are still unclear. [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] Considering the associations between inflammation and CHF, poorer outcomes and the incomplete understanding of the pathogenic mechanisms of inflammation in CHF, we aimed to explore the activation of the innate immunity in AHF by determining levels of the complement activation products (CAPs) C4d, C3a and sC5b-9 in a post hoc analysis of a population of AHF patients that was recruited in the context of a prospective study. We postulated that a higher degree of complement activation would be associated with poorer outcomes in these patients. In addition, in order to obtain a better understanding of the pathogenesis of complement-associated inflammation in AHF, we evaluated predictors of low and high CAP levels in this AHF population.
Methods

Study design and population
Unselected AHF patients presenting to the emergency department of University Hospital Basel (Switzerland) were enrolled in this prospective observational study. Men and women aged more than 18 years presenting with acute dyspnoea as their main symptom and diagnosed as having AHF were recruited. All patients underwent a clinical assessment that included a medical history, physical examination, 12-lead electrocardiogram (ECG), continuous ECG rhythm monitoring, pulse oximetry, standard blood tests and chest radiography. Treatment of patients was left to the discretion of the attending physician. The final diagnosis, phenotype of heart failure and trigger of the acute decompensation were then adjudicated using all medical records pertaining to the patients (including the results of standard investigations, responses to therapy and B-type natriuretic peptide [BNP] values) by two independent cardiologists according to current guidelines. 1 The study was conducted according to the principles of the Declaration of Helsinki and approved by the local ethics committee. Written informed consent was obtained from all participating patients. While recruitment was independent of renal function, patients with terminal kidney failure requiring chronic haemodialysis were excluded. For this analysis, patients with AHF triggered by ST-elevation myocardial infarction and patients with cardiogenic shock were also excluded.
Follow-up
The primary prognostic endpoint was all-cause mortality during follow-up. After 3, 12 and 24 months, patients were contacted by phone or by letter and were interviewed by trained researchers who were blinded to the results of the laboratory testing. Information about all cardiovascular events since presentation at the emergency department until death was obtained by the patients' family physicians, the hospital's diagnosis registry or the national registry on mortality.
Control group
In order to validate the measurements of CAP levels, we also determined CAP levels in 75 healthy blood donors. This age-and gender-unadjusted population was then used as a control group in order to compare CAP levels in AHF patients with those in healthy subjects.
Biochemical analysis
For all of the patients, venous blood samples were collected in tubes containing potassium ethylenediaminetetraacetic acid. BNP was measured immediately using the Abbott Architect assay; otherwise, samples were centrifuged and frozen at −80°C until later analysis in a dedicated core laboratory. The plasma levels of three CAPs (C4d, C3a and sC5b-9) were measured by enzyme-linked immunosorbent assay from samples taken on day 1 of hospitalisation, as well as on the day prior to discharge, using commercially available kits following the manufacturers' instructions (C3a Plus MicroVue, C4d MicroVue, SC5b-9 Plus MicroVue; all Quidel). In short, the C4d assay measures all C4d-containing fragments of C4 present in human plasma. In contrast, the C3a and sC5b-9 assays were designed to specifically detect CAPs, with the C3a assay detecting a neo-epitope on C3a (C3a-desArg) that is generated during complement activation and the sC5b-9 immunoassay measuring the concentration of soluble terminal complement complexes.
Statistical analysis
Categorical variables are expressed as numbers and percentages and continuous variables are expressed as medians and interquartile ranges.
In order to evaluate the possible activation of the complement cascade in AHF, we compared levels of CAPs in AHF patients with a control group of 75 healthy blood donors. Median values of CAP levels for AHF patients and the control group were compared by Mann-Whitney U tests, and chi-squared tests were used in order to compare the gender distribution. Due to differences in age between the patients and healthy controls, we performed an age-related subgroup analysis only for those individuals aged 60-69 years and 70-79 years. The numbers of patients in the other age groups were considered to be too low for explanatory power. In order to screen for predictors in patients with levels of all three CAPs being in the higher or lower tertile, we primarily performed univariate logistic regression. We assumed that the class of patients with levels of CAPs only in the highest or lowest tertiles had the highest or lowest activation rates of the complement cascade. In the multivariate model, we included age, sex, body mass index and all variables associated with p-values lower than 0.1 in the univariate analysis for lower or higher tertiles. Correlation analyses were performed using the Spearman rank correlation test. Receiver operating characteristic and Kaplan-Meier curves were constructed in order to assess the prognostic value of CAPs at admission with regards to 730-day mortality. Time to death during follow-up was compared between tertiles of CAPs on admission and analysed by a log-rank test. Cox regression analysis was using in order to assess the multivariable-adjusted prognostic value regarding CAPs at discharge with regards to 730-day mortality. Variables with p-values lower than 0.1 and sex were included in the multivariate analysis. The multivariate model was the reference model for testing the prognostic value of each CAP at discharge as continuous variables. All hypothesis testing was two-tailed and a p-value of 0.05 or below was considered statistically significant. All statistical analyses were performed using SPSS for Windows 22.0 (IBM) and MedCalc 11.2.1.0 (MedCalc Software).
Results
Characteristics of patients
The baseline characteristics of the 179 AHF patients are shown in Table 1 .
CAPs in AHF patients versus controls and responses to treatment
Concentrations of CAPs were significantly higher (all p < 0.001; Table 2 ) in patients with AHF as compared to a gender-and age-unadjusted control group (median age 56 years, interquartile range [IQR] 47-68 years), 23% of whom were women (p < 0.001 for comparisons with the AHF group). A subgroup analysis for patients aged between 60 and 69 years as well as between 70 and 79 years confirmed differences for levels of C4d and sC5b-9 (all p < 0.001 and p = 0.002 for sC5b-9 in individuals with aged 70-79 years), whereas no differences in levels of C3a were found in AHF patients compared to the control group (p = 0.432 and p = 0.061, respectively). Interestingly, while concentrations of C4d and sC5b-9 further increased during hospitalisation (p < 0.001), concentrations of C3a remained constant (p = NS; Figure 2) .
Concentrations of CAPs significantly correlated with each other (r = 0.64-0.76). Spreading plots with best-fitted lines between the three different CAPs are shown in Figure  3 . The correlations were moderate to high (r = 0.64, p< 0.001 for the correlation between C3a and C4d; r = 0.76, p < 0.001 for the correlation between C3a and sC5b-9; r = 0.64, p < 0.001 for the correlation between C4d and sC5b-9). C4d, C3a and sC5b-9 had weak correlations with C-reactive protein (CRP) (C4d: r = 0.20, p = 0.007; C3a: r = 0.004, p = 0.963; sC5b-9: r = 0.155, p = 0.40) and low inverse correlations with BNP (C4d: r = −0.20, p = 0.007; C3a: r = −0.18, p = 0.015; sC5b-9: r = −0.30, p < 0.001). Levels of C4d and C3a at discharge showed no correlation with BNP at discharge (p = NS), but levels of sC5b-9 had a small negative correlation with BNP at discharge (r = −0.154, p = 0.040). No correlations between CRP and the CAPs were found at discharge (p = NS).
CAPs in patients with AHF and infectious triggers
Concentrations of C4d, C3a and sC5b-9 were significantly higher when AHF was triggered by an infection as compared to other triggers (p < 0.001; Table 3 ). Notably, levels of C4d and sC5b-9 were still significantly higher in patients without an infectious trigger than in the control group (p < 0.001), while there were no differences in levels of C3a between patients with AHF but without infectious triggers and controls (p = 0.160).
CAPs in patients with AHF and coronary artery disease with or without ischaemic triggers
Plasma concentrations for the three CAPs were similar in patients with or without coronary artery disease (Supplementary Table 1 ). Patients with an ischaemic trigger of AHF had slightly but statistically significantly higher concentrations of C4d and C3a when compared to patients without an ischaemic cause (Supplementary Table 2 ). Even after exclusion of patients with an infectious trigger, there was no statistically significant difference (data not shown).
Predictors of elevated or low CAPs at AHF presentation
Univariate logistic regressions for the association of patients with all CAPs in the lower and higher tertiles are shown in Supplementary Table 3. After multivariate adjustment (Table 4) 
CAPs and long-term mortality in AHF
There were 66 events in a 2-year follow-up. The 730-day follow-ups were completed in 43/113 (38%) patients without event and the 1-year follow-ups were completed in 112/113 (99%) patients without event.
Concentrations at admission of all three investigated CAPs did not predict death within 2 years. Prognostic accuracy as quantified by the area under the curve is shown in Figure 4 , and Kaplan-Meier survival curves of AHF patients classified according to tertile of each CAP are shown in Figure 5 . Mortality rates among different tertiles of CAPs were the same (log rank = NS).
In a multivariate analysis, liver disease, estimated glomerular filtration rate and CRP at discharge were associated with mortality. Levels of CAPs at hospital discharge were not associated with long-term mortality (Table 5) .
Discussion
This prospective study explored the possible pathogenic, diagnostic and prognostic roles of complement factors in AHF by measuring plasma C4d, C3a and sC5b-9 levels.
We report four major findings. First, when compared to an unadjusted control group of healthy blood donors, plasma concentrations of all three CAPs were significantly higher in patients with AHF. However, in a subgroup analysis of patients aged 60-69 years and 70-79 years, differences could only be confirmed for levels of C4d and sC5b-9. Second, higher concentrations of C4d, C3a and sC5b-9 at admission were more often associated with an infection as a trigger of AHF, as well as with lower BNP and ALAT levels. Patients with an ischaemic trigger had slightly but not statistically significantly higher concentrations of C4d and C3a at admission. Third, levels of C4d and sC5b-9 continued to rise during hospitalisation, whereas levels of C3a remained stable, suggesting ongoing activation of the complement cascade in AHF via the classical and/or lectin pathways that is not rapidly influenced by the Subgroup analyses were performed for patients aged between 60 and 69 years (n = 15 in the control group, n = 31 in the AHF group) and 70 and 79 years (n = 15 in the control group, n = 53 in the AHF group). AHF: acute heart failure. treatment of AHF. Fourth, CAPs at admission and discharge were not associated with long-term mortality in AHF.
Our findings corroborate and extend findings from basic as well as preclinical and clinical models [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] suggesting that complement activation is mechanistically involved in adverse cardiac healing and remodelling after AMI. Complement inhibition consistently attenuated leukocyte recruitment following AMI, highlighting the critical role of the complement cascade in triggering inflammation in the ischaemic myocardium.
However, the possible roles of complement factors in AHF or CHF are still emerging. Recently, Gombos et al. examined stable outpatients with CHF and found an association between activated complement C3a and mortality or rehospitalisation due to progression of heart failure. 16 Aukrust et al. found complement activation with CHF, while treatment with intravenous immunoglobulin seemed to reduce complement activation and increase left ventricular function during a 5-month follow-up period. 14 In a recent study, Silva et al. reported lower levels of C3c and Table 3 . Levels of complement activation products (C4d, C3a and sC5b-9) in patients with infectious triggers of acute heart failure.
Infection (n = 84)
Other triggers (n = 95) p-value Other triggers include dietary indiscretion, medication malcompliance, uncontrolled hypertension, myocardial ischaemia, arrhythmia, progressive valvular disease, anaemia, thyroid disorders and pulmonary causes.
C4c being more often associated with higher levels of BNP at admission for AHF, suggesting an activation of the complement cascade in AHF. In a multivariate analysis, low C3c levels at discharge were independently associated with 6-month mortality. 27 However, while we also observed some association between CAPs and BNP levels in our study, we could not find any association between CAPs and mortality. These differences might be due to the different parameters being measured (C3c and C4c versus C4d and C3a), different methods used for their quantification (nephelometry versus enzyme immunoassays) and differences in time and character of storage of samples prior to analysis. While this is one of the first studies to explore CAPs in AHF, it is important to acknowledge several limitations. First, our study is moderate in size and recruited patients from a single institution, rendering it susceptible to inclusion bias. In this context, it is reassuring to note that the baseline characteristics of this study were similar to, for example, those of large international AHF registries. [28] [29] [30] Second, we measured only three activation products of the complement cascade, allowing only limited conclusions to be drawn on more subtle alterations in the complement system. Third, we cannot exclude effects due to the period of freezing at −80°C on complement split product levels that could only be minimised by, for example, determination of markers of complement activation in samples cooled immediately after blood collection. However, significant differences between samples from AHF patients who have undergone the same handling procedures but who have had different triggers of disease make it rather unlikely that this issue was a major confounder. In addition, control samples had also been stored at −80°C prior to use. Forth, we cannot comment on the possible role of CAPs in terminal kidney failure requiring dialysis, as such patients were excluded from our study. Fifth, patient stratification into tertiles is arbitrary and based on the In the first tertile (n = 30), patients are included who had only levels of complement activation products (C4d, C3a and sC5b-9) in the lowest tertile.
In the third tertile (n = 30), patients are included who had only levels of complement activation products in the highest tertile. Multivariate analysis included only patients without missing data (n = 151; first tertile n = 23, third tertile n = 27 hypothesis that patients with CAPs in the higher or lower tertiles have higher or lower complement activation. Sixth, the control group used for comparison of CAP levels was a cohort of healthy patients unadjusted for the baseline characteristics of the AHF cohort. Although our observation of increased complement activation is well in line with the findings of previous studies, 11, 13, 24 further studies will be required in order to determine the diagnostic as well pathogenic specificity of the observed complement activation in this AHF cohort, particularly in relation to the age, gender and comorbidity of the patients. In order to address this issue in our cohort, we performed an age-adjusted subgroup analysis in individuals aged 60-69 and 70-79 years. In both subgroups, we could confirm increased levels of C4d and sC5b-9. Interestingly, these two parameters further increased during the first days of in-hospital care and were also higher in AHF patients without an infectious trigger. This observation might point to a prominent role of the classical and/or lectin pathway of complement activation in AHF and pathogenic mechanisms that either have a delayed response to treatment or require more profound changes than those being achieved during the first days of acute medical care. Last, although our data point to a pathogenic role of complement activation in AHF, they do not allow us to dissect more detailed mechanisms, particularly with regard to the question of whether complement activation occurred locally or systemically. Our primary hypothesis was that heart failure induces complement activation that can be quantified in peripheral blood, but it is also possible that complement activation occurred more systemically, being associated with or even leading to AHF. The dissection of these mechanisms will require a more experimental approach.
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